Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-08-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha 1 is a 28-amino-acid peptide first isolated from thymosin fraction 5, a bovine thymic extract. Its sequence begins with an acetylated serine residue and carries a high proportion of acidic residues, so the molecule has a net negative charge near neutral pH. Despite the shared name, it is unrelated in sequence to the thymosin beta family. Synthetic material prepared by solid-phase peptide synthesis is identical in sequence to the natural peptide.
Several names appear in the literature for this peptide, including thymalfasin and the abbreviation T-alpha-1. Naming conventions differ among research articles, regulatory documents, and supplier catalogs, which complicates literature searches. Both synthetic and recombinant production routes yield a peptide with the same 28-residue sequence as the thymic isolate. Because the thymosin label also covers unrelated peptides, sources should be compared by sequence rather than by name alone.
The peptide occurs naturally in thymic tissue and has been detected in serum and other biological fluids. Reported concentrations are low, and reliable measurement generally requires immunoassay or mass spectrometry with an enrichment step. It is released from a larger precursor, prothymosin alpha, by proteolytic cleavage, although the enzymes involved are not fully characterized. Whether circulating levels reflect thymic output specifically remains an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Peptide | 28 amino acid residues |
| Molecular weight | Approximately 3108 Da | Depends on acetylation state |
| N-terminal modification | Acetylated | Affects charge and stability |
| Natural source | Fragment of thymosin beta-4 | Cleaved in vivo |
| Sequence length | 28 residues | Synthetic form matches natural |
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The lyophilized peptide is a white to off-white powder that dissolves freely in water and in aqueous buffers near neutral pH. Because the molecule carries a net negative charge under physiological conditions, saline and phosphate solutions are the usual vehicles, while strongly acidic media are avoided. Stock solutions are commonly divided into small aliquots so that repeated freezing and thawing can be limited, since cycling may encourage aggregation. Solubility in organic solvents is poor and those solvents are seldom used as primary diluents.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
The Randle cycle, also known as the glucose fatty-acid cycle, is a metabolic process involving the cross inhibition of glucose and fatty acids for substrates. It is theorized to play a role in explaining type 2 diabetes and insulin resistance. It was named for Philip Randle, who described it in 1963.
== Regulation == Glycogenolysis is regulated hormonally in response to blood sugar levels by glucagon and insulin, and stimulated by epinephrine during the fight-or-flight response. Insulin potently inhibits glycogenolysis. In myocytes, glycogen degradation may also be stimulated by neural signals; glycogenolysis is regulated by epinephrine and calcium released by the sarcoplasmic reticulum. Glucagon has no effect on muscle glycogenolysis. Calcium binds with calmodulin and the complex activates phosphorylase kinase.
Alonso de Ojeda (who had sailed with Columbus) reached the Guajira Peninsula in 1499. Spanish explorers, led by Rodrigo de Bastidas, made the first exploration of the Caribbean coast in 1500. Christopher Columbus navigated near the Caribbean in 1502. In 1508, Vasco Núñez de Balboa accompanied an expedition to the territory through the region of Gulf of Urabá and they founded the town of Santa María la Antigua del Darién in 1510, the first stable settlement on the continent. Santa Marta was founded in 1525, and Cartagena in 1533. Spanish conquistador Gonzalo Jiménez de Quesada led an expedition to the interior in April 1536, and christened the districts through which he passed "New Kingdom of Granada". In August 1538, he provisionally founded its capital near the Muisca cacicazgo of Muyquytá, and named it "Santa Fe". The name soon acquired a suffix and was called Santa Fe de Bogotá. Two other notable journeys by early conquistadors to the interior took place in the same period. Sebastián de Belalcázar, conqueror of Quito, traveled north and founded Cali, in 1536, and Popayán, in 1537; from 1536 to 1539, German conquistador Nikolaus Federmann crossed the Llanos Orientales and went over the Cordillera Oriental in a search for El Dorado, the "city of gold". The legend and the gold would play a pivotal role in luring the Spanish and other Europeans to New Granada during the 16th and 17th centuries. The conquistadors made frequent alliances with the enemies of different indigenous communities.
Sources: en.wikipedia.org
In May 2014, researchers announced that they had successfully introduced two new artificial nucleotides into bacterial DNA, alongside the four naturally occurring nucleotides, and by including individual artificial nucleotides in the culture media, were able to passage the bacteria 24 times; they did not create mRNA or proteins able to use the artificial nucleotides.
=== Recombinant === The production of recombinant monoclonal antibodies involves repertoire cloning, CRISPR/Cas9, or phage display/yeast display technologies. Recombinant antibody engineering involves antibody production by the use of viruses or yeast, rather than mice. These techniques rely on rapid cloning of immunoglobulin gene segments to create libraries of antibodies with slightly different amino acid sequences from which antibodies with desired specificities can be selected. The phage antibody libraries are a variant of phage antigen libraries. These techniques can be used to enhance the specificity with which antibodies recognize antigens, their stability in various environmental conditions, their therapeutic efficacy and their detectability in diagnostic applications. Fermentation chambers have been used for large scale antibody production.
== Clinical significance == GLP-1 is effective at reducing blood glucose levels. GLP-1 analogs have a significant therapeutic effect and high efficacy on diabetes treatments and hypoglycemia prevention. Proliferation effect and trophic effect on the small intestine, GLP-2 is used as a therapy to support patients with short-bowel syndrome and other underlying intestinal conditions.
Sources: en.wikipedia.org
=== Food processing levels === The level of measurement in food processing classification uses nominal or ordinal variables for qualitative grouping of food processing. Processed food classifications, such as the Nova classification, categorise processed foods and often use subjective criteria in processed foods grouping. Nominal food processing classifications group food processing according to qualitative variables, such as raw material sources, purpose of processing, traditional or novel, and type of treatment. Food processing levels (FPL) are derived from ordinal scaling of food processing impact on processed foods. Food processing levels (Table 1) indicate the object and result of food processing and provide means for the use of the extent of food processing at an ordinal scale for various purposes, e.g., processed food classification. The relative impact of FPL on the expected extent of food processing results from the combined effects of physical and chemical changes during food processing as is described in Figure 1.
The carbohydrate-insulin model (CIM) posits that obesity is caused by excess consumption of carbohydrate, which then disrupts normal insulin metabolism leading to weight gain and weight-related illnesses. It is contrasted with the mainstream energy balance model (EBM), which holds that obesity is caused by an excess in calorie consumption compared to calorie expenditure. According to the carbohydrate–insulin model, low-carbohydrate diets would be the most effective in causing long-term weight loss. Notable proponents of the carbohydrate–insulin model include Gary Taubes and David Ludwig. The CIM has been tested in mice and humans. Although some experts consider that these studies falsified the CIM, proponents disagree. Available evidence does not support the existence of a long-term advantage in weight loss for low-carbohydrate diets.
== Season 12 (2026) == Season 12 premiered on September 14, 2026 and features host John Henson as the curator of the fictional "Museum of Unnatural History." Judges Stephanie Boswell and Zac Young return, while Aarti Sequeira replaces Carla Hall.
Sources: en.wikipedia.org
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.
It is usually described as an immunomodulatory peptide rather than a classical hormone. It does not travel to a single distant organ in the manner of an endocrine hormone. Classification varies across sources, and some texts group it with thymic peptides generally.
The broad outline involves immune cell activation, but the specific molecular steps remain under investigation. Different studies report effects on dendritic cells, T cells, and natural killer cells. No single receptor has been confirmed as the sole mediator.
It is a 28-amino-acid peptide originally purified from a bovine thymic extract and later produced synthetically. It is studied mainly for its effects on immune cell function.